IPN59011 + Azzalure + Placebo
Phase 1Terminated 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Moderate Upper Facial Lines
Conditions
Moderate Upper Facial Lines, Severe Upper Facial Lines
Trial Timeline
Feb 10, 2021 → Oct 28, 2022
NCT ID
NCT04736745About IPN59011 + Azzalure + Placebo
IPN59011 + Azzalure + Placebo is a phase 1 stage product being developed by Ipsen for Moderate Upper Facial Lines. The current trial status is terminated. This product is registered under clinical trial identifier NCT04736745. Target conditions include Moderate Upper Facial Lines, Severe Upper Facial Lines.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04736745 | Phase 1 | Terminated |
Competing Products
20 competing products in Moderate Upper Facial Lines